Nasdaq: BRVE · Listed Aug 6, 2026
Braveheart Bio IPO
IPO price
$18.00
Braveheart Bio (BRVE) priced its IPO at $18.00 a share and has traded on Nasdaq since Aug 6, 2026.
BRVE today$18.00+0.00%since IPO15-min delayed · as of 4:29:23 PM EST on Nov 18, 2026
See the BRVE quoteFirst trading day · Aug 6, 2026
- IPO price
- $18.00
- above the range of $15 to $17
- First trade
- $30.20
- +67.78% from the IPO price
- First-day last trade
- $30.84
- +71.33% from the IPO price, regular session
- Raise
- $382.5M
- before the underwriters' option
These numbers are from the first trading day, Aug 6, 2026.
How BRVE did against the market
BRVE against the market, from its first trade at 12:50 ET to the last trade of the session.
- BRVE from its first trade
- +2.12%
- Against the market (QQQ)
- +2.2 pts
BRVE rose 2.1% from its first trade to the last trade of the session. That is 2.2 points better than the market.
Same-day moves do not show that BRVE caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
BRVE against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
BRVE against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Braveheart Bio '26 | $382.5M | +67.78% | +71.33% | +45.11% | +53.06% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Braveheart Bio IPO offers 21.25M shares to raise $382.5M, before any underwriters' option.
- Expected price range
- $15 to $17
- IPO price
- $18.00
- Shares offered
- 21.25M
- Money raised
- $382.5M
- Listing date
- Aug 6, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Braveheart Bio$382.5M
Where BRVE ranks
Braveheart Bio's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- BRVE$1.67B
BRVE news
The latest news and headlines about Braveheart Bio (BRVE).
- Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?positiveThe Motley Fool· Aug 10, 2026
Filings and the company
What Braveheart Bio has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Braveheart Bio discloses to the SEC on Form 8-K.
- Quarterly earningsNov 10, 2026
On November 10, 2026, Braveheart Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.
- Clinical trial resultsNov 6, 2026
On November 6, 2026, Braveheart Bio, Inc. issued a press release titled “Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026.”
- Quarterly earningsSep 8, 2026
On September 8, 2026, Braveheart Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter ended June 30, 2026.
- Charter amendmentAug 7, 2026
The Company filed its second amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on August 7, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.
About Braveheart Bio
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
- Ticker
- BRVE
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Listed
- Aug 6, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Braveheart Bio IPO price?
$18.00 a share.
When did Braveheart Bio go public?
Braveheart Bio listed on Nasdaq on Aug 6, 2026 under the ticker BRVE.
How much did the Braveheart Bio IPO raise?
$382.5M, before any underwriters' option.
How did Braveheart Bio open on its first day?
BRVE first traded at $30.20, +67.78% from the IPO price of $18.00.
How did BRVE close on its first day?
Its last regular-session trade was $30.84, +71.33% from the IPO price of $18.00.
What was the BRVE first-day trading range?
$29.42 to $31.56 in the regular session.
How many BRVE shares traded on the first day?
3.18M shares in the regular session.
How many shares did Braveheart Bio sell in its IPO?
21.25M shares.
How did BRVE do against the market on its first day?
BRVE rose 2.1% from its first trade to the last trade of the session. That is 2.2 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is BRVE listed on?
Braveheart Bio lists on Nasdaq under the ticker BRVE.
Build with Massive
Get the BRVE data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/BRVE/range/5/minute |
| Market cap | /v3/reference/tickers/BRVE |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.